CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01)] | 16 Claims |
1. A vaccine composition for eliciting in a subject an immune response against SARS-COV-2 or a variant thereof, the composition comprising
1) a first vaccine for administration as a prime vaccination, the first vaccine comprising an RNA vaccine comprising a ribonucleic acid encoding a severe acute respiratory syndrome (SARS) coronavirus spike protein (S), and
2) a second vaccine for administration as a boost vaccination, the second vaccine comprising a recombinant adenovirus comprising a first and second nucleic acid, wherein the first nucleic acid encodes a SARS coronavirus nucleocapsid protein (N) that is fused to an endosomal targeting sequence (N-ETSD), wherein the first nucleic acid encodes the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:7; and wherein the second nucleic acid encodes a SARS coronavirus spike protein (S).
|